Actively Recruiting
A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer
Led by Fudan University · Updated on 2025-08-14
800
Participants Needed
8
Research Sites
469 weeks
Total Duration
On this page
Sponsors
F
Fudan University
Lead Sponsor
P
Peking Union Medical College Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a retrospective and prospective real-world clinical study of molecular typing in the treatment of advanced thyroid cancer. The retrospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 participated hospitals from January 2020 to December 2023 were retrieved. The number of previous treatment lines was not limited. Patients who met the inclusion criteria were screened according to the inclusion and exclusion criteria. Demographic information, clinical characteristics, tumor treatment history, medication regimen, adverse reactions, molecular test results, survival follow-up results and other data were collected. The prospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 Chinese hospitals from January 2024 to April 2027 were enrolled.
CONDITIONS
Official Title
A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients volunteered to participate and signed informed consent
- Patients meet the age range accepted by each center, regardless of gender
- Histologically diagnosed locally advanced, recurrent, or metastatic thyroid cancer not suitable for surgery, including:
- Radioiodine-refractory differentiated thyroid cancer (RAIR-DTC)
- Differentiated thyroid carcinoma not suitable for iodine therapy
- Medullary thyroid carcinoma (MTC)
- Poorly differentiated thyroid cancer (PDTC) or anaplastic thyroid cancer (ATC)
- Thyroid-related pathogenic or therapeutic target gene testing performed before enrollment
You will not qualify if you...
- Participating in clinical trials of other drugs
- Pregnant or lactating
- Other conditions that make participation unsuitable as determined by researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 8 locations
1
Fujian Cancer Hospital
Fuzhou, Fujian, China
Actively Recruiting
2
Henan Cancer Hospital
Zhengzhou, Henan, China
Actively Recruiting
3
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China
Actively Recruiting
4
Caixia Liu
Hohhot, Inner Mongolia, China, 010000
Actively Recruiting
5
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032
Actively Recruiting
6
Shanxi Cancer Hospital
Shanxi, Taiyuan, China, 030000
Actively Recruiting
7
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Actively Recruiting
8
Peking union medical college hospital
Beijing, China, 100000
Actively Recruiting
Research Team
D
Dongmei Ji, M.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here